Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 17, 2018
Pharmacy Choice - Pharmaceutical News - Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017 [Sport360] - March 17, 2018

Pharmacy News Article

 10/13/17 - Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017 [Sport360]

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic effect of oral and parenteral administration of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis will be presented at The Liver Meeting 2017 the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, DC. Dr. Yaron Ilan, Professor of Medicine, and Director, Department of Medicine at Hebrew University`s Hadassah Hospital in Jerusalem, Israel, and an Immune Pharmaceuticals collaborator, will present the data in a poster.

The poster (#350), entitled Oral administration of anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel personalized therapy for immune-associated liver diseases (#350) will be presented Friday, October 20 between 12:00 and 1:30 PM ET at the Autoimmune and Cholestatic Liver Disease session. The study aimed to evaluate the biological activity and immunomodulatory effect of oral and parenteral administration of anti-eotaxin-1 antibodies in the concanavalin A (ConA) mouse model of immune hepatitis. Anti-eotaxin-1 antibodies, administered two hours prior to the induction of hepatitis, lowered eotaxin-1 levels and prevented the development of hepatitis compared to controls.

Dr. Ilan commented, These experiments showed that blocking eotaxin-1 can have a profound impact on the development of hepatic inflammation. Anti-eotaxin-1 antibodies lowered eotaxin-1 levels and were effective at blocking liver injury whether administered parenterally or orally. These results have obvious implications for the potential use of bertilimumab in liver diseases in which chronic inflammation plays a role, including NASH.

Elliot Maza, President and Chief Executive Officer of Immune Pharmaceuticals, stated, Our collaboration with Dr. Ilan has been fruitful and yielded results suggesting that blocking eotaxin-1 can have a beneficial effect in liver diseases. We will continue to explore the development of bertilimumab in liver diseases, further to our strategic business plan of focusing our resources on this first-in-class antibody.

(c) 2017 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Mar 19: Overview of Asthma Therapy for Pharmacy Professionals
Mar 20: Identification and Resolution of Clinically Relevant Drug-Drug Interactions in Adults
Mar 21: HIV Medications: Newer Drugs, Newer Guidelines
Mar 22: Treatment of Parkinson's Disease and Comorbid Conditions
Mar 25: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement